Search
Showing results for "Childhood interstitial lung disease "
Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Congratulations to Alec Truswell, Tamara Veselinović, Anastasia Phillips, and Wenna Lee for being awarded Seed Funding through the Wesfarmers Centre of Vaccines & Infectious Diseases, each valued at up to $25,000, and to Sonia McAlister, the recipient of the 2026 Riley Hughes Memorial Award in Pertussis Research.
From a handful of handmade bracelets to a fundraising milestone with life-changing impact, Nickolai’s journey is one defined by resilience, generosity, and hope.
To report on knowledge translation strategies and outcomes from the implementation of the early detection guidelines for cerebral palsy (CP) in a state-wide tertiary early intervention (EI) service and investigate the impact of social determinants on clinical services.
The impact of familial and childhood health conditions on health later in life.
Chronic suppurative otitis media (CSOM), sometimes referred to as chronic otitis media (COM), is a chronic inflammation and often polymicrobial infection (involving more than one micro-organism) of the middle ear and mastoid cavity, characterised by ear discharge (otorrhoea) through a perforated tympanic membrane. The predominant symptoms of CSOM are ear discharge and hearing loss. Antibiotics are the most common treatment for CSOM, which act to kill or inhibit the growth of micro-organisms that may be responsible for the infection.
We introduce C1 CAGE, a method for the detection of transcript 5'-ends with an original sample multiplexing strategy in the C1TM microfluidic system
A research program, which enables over 25 important respiratory research studies to be undertaken, celebrated the recruitment of its 300th participant on 14 December 2022.
The Wal-yan Respiratory Research Centre this month welcomed new PhD scholarship awardee Yaqin Alziyadat, whose exciting research work will support the Centre’s vision to ensure all children have healthy lungs for life.
A pilot clinical study has found an immunotherapy drug can dramatically increase survival rates for babies with a rare form of leukaemia, paving the way for a major international clinical trial.